摘要
造血干细胞移植(HSCT)是治疗多发性骨髓瘤(MM)的一线方案。自体造血干细胞移植(auto-HSCT)可提高患者缓解率,延长生存期。首次auto—HSCT后,未获得非常好的部分缓解及以上疗效的患者,可行二次auto—HSCT进一步改善疗效。异基因造血干细胞移植(allo—HSCT)具有治愈MM的潜能,但移植相关死亡率高,患者生存并未获益。减低剂量的allo—HSCT相关死亡率低,但复发率高,也未显示出生存优势。序贯auto—HSCT及allo—HSCT也未使患者生存明显获益。总结近期HSCT的研究进展。
Hematopoietic cell transplantation is frontline treatment of multiple myeloma (MM). Autologous hematopoietic stem cell transplantation (auto-HSCT) could improve remission rate, prolong survival time, the tandem auto-HSCT is able to make patients get further benefits for patients not achieving at least very good partial remission after the first auto-HSCT. Allologous hematopoietic stem cell transplantation (allo- HSCT) is potentially able to cure multiple myeloma, but patients achieve less benefit because of high transplant-related mortality (TRM). The TRM is low after reduced-intensity conditioning allo-HSCT, but which exhibit no survival benefit. Moreover, patients achieve no survival benefit after tandem auto-HSCT and allologous reduced-intensity conditioning transplantation. This paper reviewes recent studies about HSCT in MM.
出处
《白血病.淋巴瘤》
CAS
2012年第8期500-503,共4页
Journal of Leukemia & Lymphoma
基金
基金项目:国家自然科学基金(30872982、81172252)
关键词
多发性骨髓瘤
造血干细胞移植
Multiple myeloma
Hematopoietic stem cell transplantation